NeuroXess secures 700 million yuan in Series B funding
Chinese brain-computer interface firm NeuroXess has raised 700 million yuan to expand clinical trials and manufacturing facilities.
NeuroXess, a developer of brain-computer interface (BCI) technology, has raised 700 million yuan in a Series B funding round. The investment was co-led by SDIC Juli, Shenzhen Capital Group, and Qinzhi Capital. The proceeds are earmarked for multicenter clinical trials, regulatory approval processes, and the development of next-generation product lines.
The company specializes in implantable systems that utilize flexible electrodes and wireless power transmission. Its current technology aims to support speech and movement decoding, alongside external device control. According to the company, it has completed 65 clinical cases and launched a registration trial across 20 hospitals in July.
To scale operations, NeuroXess is constructing a 14,300-square-meter manufacturing facility. The company plans to reach an annual production capacity of 10,000 systems upon completion.